ANBL0531: response- and biology-based therapy for intermediate-risk neuroblastoma
Further reducing chemotherapy according to biology and response, including observation alone for some infants, maintained a three-year survival of 96 percent in intermediate-risk neuroblastoma.
Overview
Children's Oncology Group phase 3 study of 404 children with intermediate-risk neuroblastoma treated with two, four or eight cycles of chemotherapy depending on stage, age, biology and response, with some subgroups receiving surgery alone.
Three-year event-free survival was 83.2 percent and overall survival 94.9 percent; 12q loss and 1p loss identified patients with more events, and reduced therapy was successful in most subgroups.
- Three-year overall survival 94.9 percent; event-free survival 83.2 percent.
- Reduced therapy safe in favourable biology subgroups.
Current intermediate-risk neuroblastoma protocols minimise chemotherapy to two to eight cycles by response and biology, following this study.
- Some subgroups with unfavourable biology had lower event-free survival, prompting refinements.